Medpace Holdings Inc vs Uber Technologies Inc — how do they compare? Medpace Holdings Inc trades at $530.22 (market cap $15.08B), while Uber Technologies Inc trades at $72.2 (market cap $146.91B). The key difference: Uber Technologies Inc is far larger — about 9.7× Medpace Holdings Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Uber Technologies Inc nearer its low. Which is the better fit depends on your goals.
| MEDP | UBER | |
|---|---|---|
Market Cap | $15.08B | $146.91B |
Sector | Technology | Industrials |
52-Week High | $620.59 | $100.10 |
52-Week Low | $308.88 | $68.61 |
Enterprise Value | $14.55B | $153.24B |
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.
MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.
Uber's stock trades at $72.46, down 2.13% on the day, reflecting near-term pressure amid a bearish technical signal. Fundamentally, the company shows strong revenue growth, with 2025 revenue reaching $52.02 billion and net income of $10.05 billion, though profitability margins have moderated from 2024 peaks. Recent news highlights strategic shifts toward autonomous vehicles, including robotaxi pilots in Europe and cost-cutting measures like HR layoffs and AI spending caps to improve efficiency.
The outlook remains positive with an 81.67% analyst buy rating and a $107.64 consensus price target, suggesting significant upside. Key risks include execution challenges in autonomous vehicle integration, competitive pressures in key markets like India, and potential margin compression. Investors should weigh strong cash flow generation and market leadership against evolving regulatory and technological landscapes.
Trailing returns across standard periods
Latest headlines on both assets
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →Uber Technologies is a technology provider that matches riders with drivers, hungry people with restaurants and food delivery service providers, and shippers with carriers. The firm's on-demand technology platform could eventually be used for additional products and services, such as autonomous vehicles, delivery via drones, and Uber Elevate, which, as the firm refers to it, provides aerial ride-sharing. Uber Technologies is headquartered in San Francisco and operates in over 63 countries with over 110 million users that order rides or foods at least once a month. Approximately 76% of its gross revenue comes from ride-sharing and 22% from food delivery.
Read more on UBER →